Health & Science carried the growth as a facility there nears closure
IDEX's sales rose $73.00 M, and Health & Science Technologies supplied $52.40 M of that, about 72%. Its sales rose 14% from a year earlier, the fastest of the three segments. The same segment is where the company plans to close a facility. The filing says this quarter's restructuring expenses were $3.40 M, against $0.10 M a year earlier, and that they were mostly severance tied to employee reductions, including the anticipated closure of a facility in that segment.
Why would the fastest-growing part of the company need job cuts? The filing does not say which products or customers are moving. What it does say is that the nine-month restructuring line also carried $4.80 M of asset impairments in Fluid & Metering Technologies, the segment whose sales grew only 3.5% this quarter. The two facts sit side by side in the filing, and the filing does not connect them. A reader cannot tell from the segment table alone whether the impairment and the closure are in the same place.
What it means: the segment that carries the growth is also the one with a closure the filing calls anticipated, and restructuring has been a yearly habit, at $18.30 M in the first nine months of 2025 and $13.60 M in 2026. Will the closure end the charges, or will the next quarter bring another restructuring line? If restructuring is a yearly habit, what would make this year's cost one-time?

